- Home
- CSTL vs GHM Comparison
CSTL vs GHM Comparison
Compare CSTL & GHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- GHM
- Stock Information
- Founded
- CSTL 2007
- GHM 1936
- Country
- CSTL United States
- GHM United States
- Employees
- CSTL N/A
- GHM N/A
- Industry
- CSTL Medical Specialities
- GHM Industrial Machinery/Components
- Sector
- CSTL Health Care
- GHM Industrials
- Exchange
- CSTL Nasdaq
- GHM Nasdaq
- Market Cap
- CSTL 661.7M
- GHM 577.9M
- IPO Year
- CSTL 2019
- GHM N/A
- Fundamental
- Price
- CSTL $22.14
- GHM $59.97
- Analyst Decision
- CSTL Strong Buy
- GHM Strong Buy
- Analyst Count
- CSTL 6
- GHM 2
- Target Price
- CSTL $37.67
- GHM $60.00
- AVG Volume (30 Days)
- CSTL 296.4K
- GHM 122.6K
- Earning Date
- CSTL 11-03-2025
- GHM 11-07-2025
- Dividend Yield
- CSTL N/A
- GHM N/A
- EPS Growth
- CSTL N/A
- GHM 184.08
- EPS
- CSTL N/A
- GHM 1.26
- Revenue
- CSTL $346,269,000.00
- GHM $215,432,000.00
- Revenue This Year
- CSTL N/A
- GHM $10.98
- Revenue Next Year
- CSTL N/A
- GHM $10.59
- P/E Ratio
- CSTL N/A
- GHM $47.54
- Revenue Growth
- CSTL 20.40
- GHM 14.64
- 52 Week Low
- CSTL $14.59
- GHM $24.78
- 52 Week High
- CSTL $35.84
- GHM $64.08
- Technical
- Relative Strength Index (RSI)
- CSTL 46.56
- GHM 60.13
- Support Level
- CSTL $22.16
- GHM $55.00
- Resistance Level
- CSTL $23.19
- GHM $64.08
- Average True Range (ATR)
- CSTL 0.89
- GHM 3.12
- MACD
- CSTL -0.16
- GHM 0.43
- Stochastic Oscillator
- CSTL 10.05
- GHM 67.25
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About GHM Graham Corporation
Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.